The relative dose intensity of first-line FOLFOXIRI and FOLFOX/FOLFIRI both in combination with bevacizumab affects prognosis of metastatic colorectal cancer patients: A pooled analysis of TRIBE and TRIBE2 studies.
Saved in:
| Title: | The relative dose intensity of first-line FOLFOXIRI and FOLFOX/FOLFIRI both in combination with bevacizumab affects prognosis of metastatic colorectal cancer patients: A pooled analysis of TRIBE and TRIBE2 studies. |
|---|---|
| Authors: | Moretto R; Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy., Rossini D; Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy; Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy; Department of Experimental and Clinical Medicine, University of Florence. Oncology Unit, Careggi University Hospital, Florence, Italy., Polito MG; Department of Medical Oncology, Campus Bio-Medico University, Rome, Italy., Antoniotti C; Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy; Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy., Intini R; Oncology 1 Unit Department of Oncology, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy., Conca V; Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy; Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy., Andena P; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Carullo M; Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy; Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy., Salvatore L; Medical Oncology Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy; Medical Oncology, Università Cattolica del Sacro Cuore, Rome, Italy., Germani MM; Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy., Bergamo F; Oncology 1 Unit Department of Oncology, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy., Passardi A; Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, Meldola, Italy., Ciracì P; Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy; Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy., Tamburini E; Department of Oncology and Palliative Care, Cardinale G Panico, Tricase City Hospital, Tricase, Italy., Boccaccio C; Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy; Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy., Zaniboni A; Oncology Unit, Fondazione Poliambulanza, Brescia, Italy., Masi G; Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy; Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy., Pietrantonio F; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Lonardi S; Oncology 1 Unit Department of Oncology, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy., Cremolini C; Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy; Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy. Electronic address: chiaracremolini@gmail.com. |
| Source: | European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2025 Jun 03; Vol. 222, pp. 115470. Date of Electronic Publication: 2025 Apr 26. |
| Publication Type: | Journal Article; Clinical Trial, Phase III |
| Journal Info: | Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9005373 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0852 (Electronic) Linking ISSN: 09598049 NLM ISO Abbreviation: Eur J Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 40306121 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: The relative dose intensity of first-line FOLFOXIRI and FOLFOX/FOLFIRI both in combination with bevacizumab affects prognosis of metastatic colorectal cancer patients: A pooled analysis of TRIBE and TRIBE2 studies. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Moretto+R%22">Moretto R</searchLink>; Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy.<br /><searchLink fieldCode="AU" term="%22Rossini+D%22">Rossini D</searchLink>; Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy; Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy; Department of Experimental and Clinical Medicine, University of Florence. Oncology Unit, Careggi University Hospital, Florence, Italy.<br /><searchLink fieldCode="AU" term="%22Polito+MG%22">Polito MG</searchLink>; Department of Medical Oncology, Campus Bio-Medico University, Rome, Italy.<br /><searchLink fieldCode="AU" term="%22Antoniotti+C%22">Antoniotti C</searchLink>; Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy; Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.<br /><searchLink fieldCode="AU" term="%22Intini+R%22">Intini R</searchLink>; Oncology 1 Unit Department of Oncology, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.<br /><searchLink fieldCode="AU" term="%22Conca+V%22">Conca V</searchLink>; Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy; Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.<br /><searchLink fieldCode="AU" term="%22Andena+P%22">Andena P</searchLink>; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.<br /><searchLink fieldCode="AU" term="%22Carullo+M%22">Carullo M</searchLink>; Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy; Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.<br /><searchLink fieldCode="AU" term="%22Salvatore+L%22">Salvatore L</searchLink>; Medical Oncology Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy; Medical Oncology, Università Cattolica del Sacro Cuore, Rome, Italy.<br /><searchLink fieldCode="AU" term="%22Germani+MM%22">Germani MM</searchLink>; Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.<br /><searchLink fieldCode="AU" term="%22Bergamo+F%22">Bergamo F</searchLink>; Oncology 1 Unit Department of Oncology, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.<br /><searchLink fieldCode="AU" term="%22Passardi+A%22">Passardi A</searchLink>; Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, Meldola, Italy.<br /><searchLink fieldCode="AU" term="%22Ciracì+P%22">Ciracì P</searchLink>; Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy; Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.<br /><searchLink fieldCode="AU" term="%22Tamburini+E%22">Tamburini E</searchLink>; Department of Oncology and Palliative Care, Cardinale G Panico, Tricase City Hospital, Tricase, Italy.<br /><searchLink fieldCode="AU" term="%22Boccaccio+C%22">Boccaccio C</searchLink>; Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy; Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.<br /><searchLink fieldCode="AU" term="%22Zaniboni+A%22">Zaniboni A</searchLink>; Oncology Unit, Fondazione Poliambulanza, Brescia, Italy.<br /><searchLink fieldCode="AU" term="%22Masi+G%22">Masi G</searchLink>; Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy; Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.<br /><searchLink fieldCode="AU" term="%22Pietrantonio+F%22">Pietrantonio F</searchLink>; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.<br /><searchLink fieldCode="AU" term="%22Lonardi+S%22">Lonardi S</searchLink>; Oncology 1 Unit Department of Oncology, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.<br /><searchLink fieldCode="AU" term="%22Cremolini+C%22">Cremolini C</searchLink>; Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy; Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy. Electronic address: chiaracremolini@gmail.com. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%229005373%22">European journal of cancer (Oxford, England : 1990)</searchLink> [Eur J Cancer] 2025 Jun 03; Vol. 222, pp. 115470. <i>Date of Electronic Publication: </i>2025 Apr 26. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Clinical Trial, Phase III – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier+Science+Ltd%22">Elsevier Science Ltd </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>9005373 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1879-0852 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2209598049%22">09598049 </searchLink><i>NLM ISO Abbreviation: </i>Eur J Cancer <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40306121 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.ejca.2025.115470 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 115470 Titles: – TitleFull: The relative dose intensity of first-line FOLFOXIRI and FOLFOX/FOLFIRI both in combination with bevacizumab affects prognosis of metastatic colorectal cancer patients: A pooled analysis of TRIBE and TRIBE2 studies. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Moretto R – PersonEntity: Name: NameFull: Rossini D – PersonEntity: Name: NameFull: Polito MG – PersonEntity: Name: NameFull: Antoniotti C – PersonEntity: Name: NameFull: Intini R – PersonEntity: Name: NameFull: Conca V – PersonEntity: Name: NameFull: Andena P – PersonEntity: Name: NameFull: Carullo M – PersonEntity: Name: NameFull: Salvatore L – PersonEntity: Name: NameFull: Germani MM – PersonEntity: Name: NameFull: Bergamo F – PersonEntity: Name: NameFull: Passardi A – PersonEntity: Name: NameFull: Ciracì P – PersonEntity: Name: NameFull: Tamburini E – PersonEntity: Name: NameFull: Boccaccio C – PersonEntity: Name: NameFull: Zaniboni A – PersonEntity: Name: NameFull: Masi G – PersonEntity: Name: NameFull: Pietrantonio F – PersonEntity: Name: NameFull: Lonardi S – PersonEntity: Name: NameFull: Cremolini C IsPartOfRelationships: – BibEntity: Dates: – D: 03 M: 06 Text: 2025 Jun 03 Type: published Y: 2025 Identifiers: – Type: issn-electronic Value: 1879-0852 Numbering: – Type: volume Value: 222 Titles: – TitleFull: European journal of cancer (Oxford, England : 1990) Type: main |
| ResultId | 1 |
